3rd Quarter - Report

WILLIAMS AND JENSEN, PLLC for ASTRAZENECA PHARMACEUTICALS LP (FORMERLY ASTRAZENECA PHARMACEUTICALS GROUP)

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Veterans VET

Pharmaceutical sourcing from non-Trade Agreement Act countries.

LobbyistCovered position, as disclosed
MATTHEW B HOEKSTRA —
GEORGE OLSEN —

Contacted: State, Dept of (DOS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE

Foreign Relations FOR

Market access issues.

LobbyistCovered position, as disclosed
ERIC STEWART New COS and Deputy Asst. Sec., Dept. of Commerce

Contacted: State, Dept of (DOS); SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Medicare prescription drug benefit. Drug rebates for Medicare Part D. Part D benefit structure. Indpendent Payment Advisory Board (IPAB).

LobbyistCovered position, as disclosed
JACK STEVEN HART —
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
KARINA LYNCH —
ERIN BOOK MULLEN —
GEORGE OLSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Commerce, Dept of (DOC)

Taxation/Internal Revenue Code TAX

Tax issues affecting the pharmaceutical industry, tax reform issues.

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
TESS ILLOS —
GEORGE OLSEN —

Contacted: State, Dept of (DOS); Commerce, Dept of (DOC); SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Implementation of Patient Protection and Affordable Care Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages; Work on 21st Century Cures Initiative

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
KARINA LYNCH —
MELINDA M MAXFIELD —
ERIN BOOK MULLEN —
GEORGE OLSEN —
ANTHONY J RODA —

Contacted: Commerce, Dept of (DOC); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; SENATE

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
ASTRAZENECA TREASURY LIMITED United Kingdom United Kingdom 100.0% —
ASTRAZENECA AB Sweden Sweden 90.3% —
ASTRAZENECA PLC United Kingdom United Kingdom 100.0% —
ASTRAZENECA INTERMEDIATE HOLDINGS LTD. United Kingdom United Kingdom 100.0% —
ASTRAZENECA UK LIMITED United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.